These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 7702065)

  • 21. Interaction of heparinoids with platelets: comparison with heparin and low molecular weight heparins.
    Messmore HL; Griffin B; Koza M; Seghatchian J; Fareed J; Coyne E
    Semin Thromb Hemost; 1991; 17 Suppl 1():57-9. PubMed ID: 1712512
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Heparin induced platelet aggregation: in vitro confirmation of thrombotic complications associated with heparin therapy.
    Hussey CV; Bernhard VM; McLean MR; Fobian JE
    Ann Clin Lab Sci; 1979; 9(6):487-93. PubMed ID: 518011
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Heparin-associated thrombocytopenia in maintenance hemodialysis patients.
    Leehey DJ; Kanak RJ; Messmore HL; Nawab ZM; Popli S; Ing TS
    Int J Artif Organs; 1987 Nov; 10(6):390-2. PubMed ID: 3443522
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A prospective study of the prevalence of heparin-induced antibodies and other associated thromboembolic risk factors in pediatric patients undergoing hemodialysis.
    Skouri H; Gandouz R; Abroug S; Kraiem I; Euch H; Gargouri J; Harbi A
    Am J Hematol; 2006 May; 81(5):328-34. PubMed ID: 16628723
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of circuit and AV fistula clotting and detection of anti-PF4/heparin complex antibodies in hemodialysis patients suspected of having heparin-induced thrombocytopenia.
    Matsuo T; Wanaka K; Walenga JM
    Clin Appl Thromb Hemost; 2013; 19(1):73-8. PubMed ID: 22345486
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Recombinant tissue plasminogen activator is a useful alternative to heparin in priming quinton permcath.
    Schenk P; Rosenkranz AR; Wölfl G; Hörl WH; Traindl O
    Am J Kidney Dis; 2000 Jan; 35(1):130-6. PubMed ID: 10620554
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Heparin-induced thrombocytopenia in renal failure.
    Hall AV; Clark WF; Parbtani A
    Clin Nephrol; 1992 Aug; 38(2):86-9. PubMed ID: 1516285
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Standard heparin versus low-molecular-weight heparin. A medium-term comparison in hemodialysis.
    Stefoni S; Cianciolo G; Donati G; Colì L; La Manna G; Raimondi C; Dalmastri V; Orlandi V; D'Addio F
    Nephron; 2002; 92(3):589-600. PubMed ID: 12372942
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Survival of primary arteriovenous fistula in 463 patients on chronic hemodialysis.
    Puskar D; Pasini J; Savić I; Bedalov G; Sonicki Z
    Croat Med J; 2002 Jun; 43(3):306-11. PubMed ID: 12035137
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anti-heparin-platelet factor 4 antibody is a risk factor for vascular access obstruction in patients undergoing hemodialysis.
    Lee EY; Hwang KY; Yang JO; Hong SY
    J Korean Med Sci; 2003 Feb; 18(1):69-72. PubMed ID: 12589090
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intravenous and subcutaneous weight-based dosing of the low molecular weight heparin tinzaparin (Innohep) in end-stage renal disease patients undergoing chronic hemodialysis.
    Hainer JW; Sherrard DJ; Swan SK; Barrett JS; Assaid CA; Fossler MJ; Cox DS; Williams RM; Pittenger AL; Stephenson CA; Hua TA
    Am J Kidney Dis; 2002 Sep; 40(3):531-8. PubMed ID: 12200805
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Heparin-induced thrombocytopenia with pseudo-pulmonary embolism in a patient who was newly introduced to hemodialysis treatment].
    Watarai R; Aoyama T; Kamata M; Miyazawa M; Ogawa M; Okina C; Murano J; Tanaka K; Aoyama M; Nakano M; Sano T; Kamata K
    Nihon Jinzo Gakkai Shi; 2015; 57(7):1248-52. PubMed ID: 26665617
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The safety of heparins in end-stage renal disease.
    Sonawane S; Kasbekar N; Berns JS
    Semin Dial; 2006; 19(4):305-10. PubMed ID: 16893408
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anticoagulation with r-hirudin in regular haemodialysis with heparin-induced thrombocytopenia (HIT II). The first long-term application of r-hirudin in a haemodialysis patient.
    Nowak G; Bucha E; Brauns I; Czerwinski R
    Wien Klin Wochenschr; 1997 May; 109(10):354-8. PubMed ID: 9200807
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Platelet aggregation studies for the diagnosis of heparin-induced thrombocytopenia.
    Isenhart CE; Brandt JT
    Am J Clin Pathol; 1993 Mar; 99(3):324-30. PubMed ID: 8447295
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hemodialysis without anticoagulation.
    Sanders PW; Taylor H; Curtis JJ
    Am J Kidney Dis; 1985 Jan; 5(1):32-5. PubMed ID: 3881017
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Heparin-induced thrombocytopenia. Perspectives in a therapeutic dilemma].
    Linde N; Tsakiris DA; Vogt A; Marbet GA
    Vasa; 1991; 20(2):157-63. PubMed ID: 1652180
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The prevalence of antibodies to the platelet factor 4 -heparin complex and association with access thrombosis in patients on chronic hemodialysis.
    Carrier M; Knoll GA; Kovacs MJ; Moore JC; Fergusson D; Rodger MA
    Thromb Res; 2007; 120(2):215-20. PubMed ID: 17098277
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Primary arteriovenous fistulas in the forearm for hemodialysis: effect of miscellaneous factors in fistula patency.
    Erkut B; Unlü Y; Ceviz M; Becit N; Ateş A; Colak A; Koçak H
    Ren Fail; 2006; 28(4):275-81. PubMed ID: 16771241
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Thrombocytopenia and anaphylaxis secondary to heparin in a hemodialysis patient.
    Tejedor Alonso MA; López Revuelta K; García Bueno MJ; Casas Losada ML; Rosado Ingelmo A; Gruss Vergara E; Vila Albelda C; Moro Moro M
    Clin Nephrol; 2005 Mar; 63(3):236-40. PubMed ID: 15786828
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.